Review
doi: 10.1358/dot.2006.42.1.957357.
Fabry disease
Affiliations
- PMID: 16511611
- DOI: 10.1358/dot.2006.42.1.957357
Item in Clipboard
Review
Fabry disease
Drugs Today (Barc).
2006 Jan.
Abstract
Fabry disease is an inherited enzyme deficiency of galactosidase A that results in various phenotypes: classic, cardiac or renal. It can present variably and may represent an important cause of occult neurological and cardiac syndromes and renal failure. Preclinical and clinical studies demonstrate effectiveness of enzyme infusion in controlling and preventing these manifestations of the disease.
Copyright 2006 Prous Science
Republished in
-
Fabry disease.Timely Top Med Cardiovasc Dis. 2006 Apr 1;10:E8. Timely Top Med Cardiovasc Dis. 2006. PMID: 17066133
Similar articles
-
Fabry disease: enzyme replacement therapy.J Eur Acad Dermatol Venereol. 2003 Nov;17(6):676-9. doi: 10.1046/j.1468-3083.2003.00831.x. J Eur Acad Dermatol Venereol. 2003. PMID: 14761135
-
Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.Nephrol Ther. 2006 Jan;2 Suppl 2:S172-85. Nephrol Ther. 2006. PMID: 17373219
-
Enzyme replacement in Anderson-Fabry disease.Lancet. 2003 Jan 25;361(9354):352. doi: 10.1016/S0140-6736(03)12357-4. Lancet. 2003. PMID: 12559898 No abstract available.
-
Spotlight on agalsidase beta in Fabry disease.BioDrugs. 2007;21(4):269-71. doi: 10.2165/00063030-200721040-00007. BioDrugs. 2007. PMID: 17628124 Review.
-
[Current status and future prospect of enzyme replacement therapy for Fabry disease].Rinsho Shinkeigaku. 2019 Jun 22;59(6):335-338. doi: 10.5692/clinicalneurol.cn-001246. Epub 2019 May 29. Rinsho Shinkeigaku. 2019. PMID: 31142708 Review. Japanese.
Cited by
-
Mutation patterns in human alpha-galactosidase A.Mol Divers. 2010 Feb;14(1):147-54. doi: 10.1007/s11030-009-9158-4. Epub 2009 May 26. Mol Divers. 2010. PMID: 19468850 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
